Active monitoring (Deferred Treatment or Watchful Waiting) in the treatment of prostate cancer

European Urology

Volumn 40, Issue 5, 2001, Pages 488-494

  Schmid, Hans Peter ^a   Adolfsson, Jan ^b   Aus, Gunnar ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Swedish Council on Technology Assessment in Health Care   (Sweden)

^c RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

Active monitoring, review; Prostatic neoplasms, treatment

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; DISEASE PROGRESSION; HUMANS; LIFE EXPECTANCY; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035733145     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049824     Document Type: Review

References (57)

1. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
2. High grade prostatic intraepithelial neoplasia and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases
3. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
4. Non-palpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate-specific antigen level and needle biopsy findings
5. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
6. Decline in prostate cancer mortality from 1987 to 1997, and an update on incidence trends in Olmsted County, Minnesota
7. Prostate cancer registration in four Swedish regions 1996
8. Management of early prostatic cancer in the Nordic countries: Variations in clinical policies and physicians' attitudes toward radical treatment options. A NEMT survey
9. Radical surgery versus radiotherapy for adenocarcinoma of the prostate
10. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study
11. Swedish randomized trial of radical prostatectomy versus watchful waiting
12. The Prostate Cancer Intervention Versus Observation Trial (PIVOT)
13. Is delayed treatment justified in carcinoma of the prostate
14. Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate
15. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: A randomized multicenter study with 15 years of follow-up
16. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
17. Deferred treatment of clinically localized low-grade prostate cancer: Actual 10 years' and projected 15 years' follow-up of the Karolinska Series
18. Patterns of treatment of patients with prostate cancer initially managed by surveillance: Results from the CaPSURE database. Cancer of the Prostate Strategic Urological Research Endevour
19. Results of conservative management of clinically localized prostate cancer
20. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer
21. Observation alone in the management of localized prostate cancer: The natural history of untreated disease
22. Contemporary expectant therapy series: A viewpoint
23. An analysis of watchful waiting for clinically localized prostate cancer
24. Recent results on management of palpable clinically localized prostate cancer
25. Cancer of the prostate: Is there a need for aggressive treatment?
26. Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate
27. Prospective, conservative management of localized prostate cancer
28. Expectant management of localized prostate cancer
29. Deferred treatment in clinically localised prostatic carcinoma
30. Natural history of localized prostate: A population-based study in 223 untreated patients
31. High 10-year survival rate in patients with early, untreated prostatic cancer
32. Population-based study of long-term survival in patients with clinically localised prostate cancer
33. Management of stage T1a prostate cancer
34. Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: A preliminary report
35. Staging of incidentally detected prostate cancer: Role of repeat resection, prostate-specific antigen, needle biopsy, and imaging
36. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden
37. Making the most out of six systematic sextant biopsies
38. The Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma and combined histological grading and clinical staging
39. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
40. Statistical considerations when assessing outcomes following treatment for prostate cancer
41. TibblinG: Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden
42. Natural history of changes in prostate-specific antigen in early stage prostate cancer
43. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical Prostatectomy treated patients
44. Observation of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy
45. Observations of prostate-specific antigen time in Japanese patients with nonmetastatic prostate carcinoma
46. Evaluation of changes in prostate-specific antigen in clinically localized prostate cancer managed without initial therapy
47. Pretreatment prostate-specific antigen doubling times use in patients before radical prostatectomy
48. Long-term survival and mortality in prostate cancer treated with noncurative intent
49. Prostate cancr mortality in patients surviving more than 10 years after diagnosis
50. Mortality of patients with clinically localised prostate cancer treated with observation for 10 years or longer: A population-based study
51. The burden of prostate cancer from diagnosis until death
52. Prostate cancer and long-term survival
53. Localized prostate cancer and 30 years of follow-up in a population-based setting
54. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age
55. Deferred treatment of locally advanced nonmetastatic prostate cancer: A long-term follow-up
56. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
57. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial